PPD hires FDA, Novartis and Genentech veteran in new dual role

Jonca Bull has seen a series of regulatory roles across biopharma and FDA.

PPD has taken on the former assistant commissioner and director of its Office of Minority Health at the FDA, Jonca Bull, M.D., as VP of PPD Consulting, as well as vice president of ophthalmology, within global product development.

Using her experience at the FDA as well as her stints at Novartis and Genentech, Bull will help run PPD’s consulting unit and its regulatory side. The business provides full drug development design and planning facilities.

The company's global product development teams, meanwhile, will coordinate a variety of services and insight from therapeutic thought leaders to create customized development strategies to meet client needs.

Whitepaper

Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

“Jonca possesses a wealth of experience in the regulatory arena, including with the FDA and in the pharmaceutical industry,” said Rob Dow, chief medical officer for PPD.

“Her experience working closely with pharmaceutical clients, as well as health and regulatory authorities, will help enhance patient engagement for PPD clients in developing life-changing therapies.”

Suggested Articles

Data firm Syapse has begun working with the FDA to help bring real-world evidence to bear on the agency’s decisions to approve cancer drugs.

The People-Centered Research Foundation tapped Datavant to de-identify real-world data across its national clinical research network.

Boehringer Ingelheim and MD Anderson Cancer Center have joined forces to create a “virtual” R&D hub so the pair can work on cancer drugs.